# Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

> **NCT04649060** · PHASE3 · TERMINATED · sponsor: **Oncopeptides AB** · enrollment: 54 (actual)

## Conditions studied

- Relapsed Multiple Myeloma
- Relapsed-Refractory Multiple Myeloma

## Interventions

- **DRUG:** Melflufen
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04649060
- **Lead sponsor:** Oncopeptides AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-21
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-02-07
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** The sponsor decided to terminate the study due to financial issues following an FDA request for a partial clinical hold.
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649060, "Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04649060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*